Trial reportEuropean journal of nuclear medicine and molecular imaging2025
Prospective comparison of
Trial report in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03537391 (Imaging for Prostate Cancer Metastasis Detection - Traditional Imaging), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imaging for Prostate Cancer Metastasis Detection - Traditional Imaging (Bone Scan and CT) Versus PSMA-PET-CT, SPECT-CT and Whole-Body MRI
Who cites it
8 citing papers in PubMed.
- Head-to-head comparison of [¹⁸F]F-PSMA-1007 PET/CT and [⁶⁸Ga]Ga-PSMA-11 PET/CT for intraprostatic tumour detection and localisation using histopathology as reference: A prospective single-centre diagnostic accuracy study.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Implications for Radiation Microboosting Based on Pathology Correlations With Prostate-Specific Membrane Antigen and Multiparametric Magnetic Resonance Imaging Findings.Advances in radiation oncology · 2026Article
- Navigating discordant findings in multimodality imaging of prostate cancer in the MRI and PSMA-PET era.La Radiologia medica · 2026Review
- Multimodal data fusion: integrating PET/MRI and liquid biopsy for a holistic view of cancer biology.Frontiers in oncology · 2026Review
- Differences in residual lesion detection after treatment of metastatic prostate cancer based on dual-tracer PET/CT.Frontiers in oncology · 2026Article
- Impact ofDiagnostics (Basel, Switzerland) · 2025Article
- Multimodal imaging deep learning model for predicting extraprostatic extension in prostate cancer using MpMRI and 18 F-PSMA-PET/CT.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo prospectively compare the ability of
methodsMen with newly diagnosed unfavourable intermediate or high-risk PCa underwent
results19 patients with 39 intraprostatic lesions in histopathology were included. The overall lesion detection rates for PET/CT were 84.6% and 82.1% for two independent readers, compared to 74.4% and 46.2% for MRI readers. The detection rates of index lesions were 94.7% for PET/CT and 74.0-84.0% for MRI, whereas those of non-index lesions were 70.0-75.0% for PET/CT and 20.0-65.0% for MRI. For detecting EPE, AUC values were 0.500-0.591 for PET/CT and 0.648-0.682 for MRI. For detecting SVI, AUC values ranged from 0.629 to 0.700 across both modalities. SUVmax showed a weak correlation with immunohistochemical expression of PSMA multiplied by lesion diameter (Spearman's ρ = 0.427, p = 0.013). Lesion diameters measured using 30% and 40% of SUVmax, as well as prostate SUVbackground x2, showed the closest agreement with histopathological measurements.
conclusionCLINICAL
trial registrationClinicaltrials.gov ID: NCT03537391. Registered 25 May 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.